Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. The company is headquartered in Cambridge, Cambridgeshire and currently employs 61 full-time employees. The firm is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The firm is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The firm is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.